Markets:

Overview

News

Currencies

International

Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Analyst Expectations for bluebird bio's Future ↗

March 07, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗

March 07, 2023

Via Benzinga

1 Beaten-Down Stock That Has a Lot to Prove in 2023 ↗

February 08, 2023

This biotech looks like a high-risk, high-reward play.

Via The Motley Fool

What 4 Analyst Ratings Have To Say About bluebird bio ↗

January 24, 2023

Via Benzinga

Skechers To Rally 40%? Here Are 10 Other Analyst Forecasts For Monday ↗

January 23, 2023

Credit Suisse raised the price target for Exelon Corporation (NASDAQ: EXC) from $42 to $46. Credit Suisse analyst Nicholas Campanella maintained an Outperform rating. Exelon shares fell 0.1% to $42.32...

Via Benzinga

Why Bluebird Bio (BLUE) Stock Is Getting Hammered ↗

January 18, 2023

Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower by 10.0% to $6.55 Wednesday morning after the company announced a proposed public offering of common stock.

Via Benzinga

2 Risky Stocks That Could Soar in 2023 ↗

December 06, 2022

These "exciting" companies aren't for everyone.

Via The Motley Fool

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics? ↗

January 22, 2023

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.

Via The Motley Fool

Tesla, Amazon, bluebird, Netflix, Discover Financial: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 18, 2023

Major Wall Street indices closed over 1.2% lower on Wednesday, dragged by renewed concerns of a recession as U.S. retail sales declined by the most in 12 months, down 1.1% in December as against...

Via Benzinga

PNC Financial, bluebird bio And Other Big Stocks Moving Lower On Wednesday ↗

January 18, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 300 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Is Zomedica (ZOM) Stock Up Today? ↗

January 18, 2023

Zomedica (ZOM) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies.

Via InvestorPlace

Looking Into bluebird bio's Return On Capital Employed ↗

November 30, 2022

Via Benzinga

Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results ↗

January 18, 2023

Moderna (MRNA) stock is on the move Wednesday alongside positive results from its latest Phase 3 mRNA-1345 vaccine trial.

Via InvestorPlace

Moderna Gets Good News, but Another Biotech Stock Is Falling Again ↗

January 18, 2023

The Nasdaq looked poised for modest gains once again on Wednesday.

Via The Motley Fool

Why is Bluebird Bio (BLUE) Stock Down 9% Today? ↗

January 18, 2023

Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 18, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 18, 2023

We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!

Via InvestorPlace

2 Stocks That Could Double Your Money in 2023 ↗

January 07, 2023

These biotechs could crush the market, but there is more to the story.

Via The Motley Fool

Newly Approved Drugs In US Command Over $200,000 On An Average ↗

January 05, 2023

The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.

Via Benzinga

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗

December 30, 2022

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

Via The Motley Fool

After Doubling in the Past 6 Months, Is This Stock a Buy? ↗

December 24, 2022

This company has had a solid year, but there is still plenty of work ahead.

Via The Motley Fool

FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol ↗

December 19, 2022

Via Benzinga

BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment ↗

December 19, 2022

In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment.

Via InvestorPlace

Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting ↗

December 13, 2022

Via Benzinga

Why Bluebird Bio Stock Crushed the Market Today ↗

December 12, 2022

The company looks set to continue its good momentum in the early part of next year.

Via The Motley Fool

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position ↗

November 30, 2022

Via Benzinga

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗

November 23, 2022

Via Benzinga

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

2 Growth Stocks That Could Double in 2023 ↗

November 17, 2022

Both are lagging the market this year.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

bluebird bio, Inc. - Common Stock (NQ:BLUE)

Headline News about bluebird bio, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today